These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25379431)

  • 21. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL; Chia S; Shang CY; Gau SS
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
    Kratz O; Studer P; Baack J; Malcherek S; Erbe K; Moll GH; Heinrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):81-9. PubMed ID: 22227291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Light up ADHD: II. Neuropharmacological effects measured by near infrared spectroscopy: is there a biomarker?
    Grazioli S; Mauri M; Crippa A; Maggioni E; Molteni M; Brambilla P; Nobile M
    J Affect Disord; 2019 Feb; 244():100-106. PubMed ID: 30332620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
    Schwartz S; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
    Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
    J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex.
    Gilbert DL; Ridel KR; Sallee FR; Zhang J; Lipps TD; Wassermann EM
    Neuropsychopharmacology; 2006 Feb; 31(2):442-9. PubMed ID: 16034446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
    Maziade M; Rouleau N; Lee B; Rogers A; Davis L; Dickson R
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):709-18. PubMed ID: 20035589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning.
    Wietecha L; Young J; Ruff D; Dunn D; Findling RL; Saylor K
    Clin Neuropharmacol; 2012; 35(3):125-33. PubMed ID: 22561876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
    Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of atomoxetine on executive function impairments in adults with ADHD.
    Brown TE; Holdnack J; Saylor K; Adler L; Spencer T; Williams DW; Padival AK; Schuh K; Trzepacz PT; Kelsey D
    J Atten Disord; 2011 Feb; 15(2):130-8. PubMed ID: 20026871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement.
    Gilbert DL; Zhang J; Lipps TD; Natarajan N; Brandyberry J; Wang Z; Sallee FR; Wassermann EM
    Clin Neurophysiol; 2007 Aug; 118(8):1835-41. PubMed ID: 17588810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.